Emerging Antitrust Issues—Implications to the Life Sciences Industry


Allegations of antitrust violations, particularly in the life sciences industry, have become more prevalent in recent years. In addition to cases brought by private litigants, the Food and Drug Administration and the Federal Trade Commission (FTC) are working together to prevent anticompetitive business practices. Mergers and acquisitions among pharmaceutical companies, as well as their conduct with regard to the expiration of their drug patents, have been closely monitored by the FTC. 

In this webcast, Edgeworth Partner Dr. George Korenko will join other thought leaders to present on antitrust litigation and regulatory trends, their implications on the life sciences industry, and best practices for compliance. 

Related Materials


Jump to Page

This website uses cookies to improve functionality and performance. By continuing to use this website, you agree to the use of cookies in accordance with our Privacy Policy.  If you are a California resident, read our California Information Practices.